Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Sections
Innovations in Cancer Drug Development Research
share announcement

Innovations in Cancer Drug Development Research

A topical collection in Cancers (ISSN 2072-6694). This collection belongs to the section "Cancer Drug Development".

Viewed by 785

Editor

Prof. Dr. Anupam Bishayee

grade E-Mail Website
Collection Editor
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA
Interests: bioactive natural compounds; cancer prevention; phytopharmacology; molecular mechanisms
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

This Topical Collection, titled “Innovations in Cancer Drug Development Research”, will bring together groundbreaking research into cancer drug development. Currently, scientists and researchers are exploring revolutionary approaches to enhance the efficacy of cancer treatments and alleviate side effects experienced by patients. Innovations encompass the discovery of new drug targets, the development of more efficient drug delivery systems, and the utilization of advanced technologies and methods, such as gene editing and artificial intelligence, to expedite the discovery and development of new drugs. Through these innovations, researchers will personalize treatments and both gain a better understanding of and learn how to overcome drug resistance, providing cancer patients with more viable and enduring therapeutic options. Ongoing innovative research in this field continues to advance cancer treatments, offering patients greater hope and improved chances of survival.

Original research papers reporting in vitro and in vivo data; authoritative systematic, and perspective reviews; clinical trials; and reports on meta-analysis will be considered. Various relevant topics include, but are not limited to, the following areas:

  • Anticancer drug discovery;
  • Drug development;
  • Chemotherapeutic agents;
  • Hormonal agents;
  • Targeted agents;
  • Immunological agents;
  • Preventive therapeutic agents;
  • Radiopharmaceuticals;
  • Combination therapies;
  • Structure–activity relationship;
  • Dereplication and molecular networking;
  • Pharmacokinetics of anticancer agents;
  • Emerging hallmarks;
  • Precision medicine;
  • Personalized therapy;
  • Artificial intelligence.

Prof. Dr. Anupam Bishayee
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug resistance
  • novel drug formulation
  • novel drug delivery

Published Papers (2 papers)

Download All Papers

2024

15 pages, 658 KiB  
Review
Survivin as a Therapeutic Target for the Treatment of Human Cancer
by Qiang Wang and Mark I. Greene
Cancers 2024, 16(9), 1705; https://doi.org/10.3390/cancers16091705 (registering DOI) - 27 Apr 2024
Viewed by 124
Abstract
Survivin was initially identified as a member of the inhibitor apoptosis (IAP) protein family and has been shown to play a critical role in the regulation of apoptosis. More recent studies showed that survivin is a component of the chromosome passenger complex and [...] Read more.
Survivin was initially identified as a member of the inhibitor apoptosis (IAP) protein family and has been shown to play a critical role in the regulation of apoptosis. More recent studies showed that survivin is a component of the chromosome passenger complex and acts as an essential mediator of mitotic progression. Other potential functions of survivin, such as mitochondrial function and autophagy, have also been proposed. Survivin has emerged as an attractive target for cancer therapy because its overexpression has been found in most human cancers and is frequently associated with chemotherapy resistance, recurrence, and poor survival rates in cancer patients. In this review, we discuss our current understanding of how survivin mediates various aspects of malignant transformation and drug resistance, as well as the efforts that have been made to develop therapeutics targeting survivin for the treatment of cancer. Full article
►▼ Show Figures

Figure 1

51 pages, 5584 KiB  
Review
Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer
by Xin Gu and Tamara Minko
Cancers 2024, 16(8), 1589; https://doi.org/10.3390/cancers16081589 - 20 Apr 2024
Viewed by 361
Abstract
Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers, presents significant challenges in diagnosis and treatment due to its aggressive, metastatic nature and lack of early detection methods. A key obstacle in PDAC treatment is the highly complex tumor environment characterized by dense [...] Read more.
Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers, presents significant challenges in diagnosis and treatment due to its aggressive, metastatic nature and lack of early detection methods. A key obstacle in PDAC treatment is the highly complex tumor environment characterized by dense stroma surrounding the tumor, which hinders effective drug delivery. Nanotechnology can offer innovative solutions to these challenges, particularly in creating novel drug delivery systems for existing anticancer drugs for PDAC, such as gemcitabine and paclitaxel. By using customization methods such as incorporating conjugated targeting ligands, tumor-penetrating peptides, and therapeutic nucleic acids, these nanoparticle-based systems enhance drug solubility, extend circulation time, improve tumor targeting, and control drug release, thereby minimizing side effects and toxicity in healthy tissues. Moreover, nanoparticles have also shown potential in precise diagnostic methods for PDAC. This literature review will delve into targeted mechanisms, pathways, and approaches in treating pancreatic cancer. Additional emphasis is placed on the study of nanoparticle-based delivery systems, with a brief mention of those in clinical trials. Overall, the overview illustrates the significant advances in nanomedicine, underscoring its role in transcending the constraints of conventional PDAC therapies and diagnostics. Full article
►▼ Show Figures

Figure 1

Back to TopTop